Perspectives in PML: A unifying framework for PML function

Frontiers in Bioscience

Volumn 14, Issue 2, 2009, Pages 497-509

  Borden, Katherine L B ^a   Culjkovic, Biljana ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

eIF4E; Nd10; Nuclear bodies; PML; Review; RNA regulon

Indexed keywords

MAMMALIA;

NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

CELL NUCLEUS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; RNA PROCESSING;

CELL NUCLEUS; HUMANS; NUCLEAR PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 63849293624     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3258     Document Type: Review

References (118)

1. C. Szostecki, H. H. Guldner, H. J. Netter and H. Will: Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol, 145(12), 4338-47(1990)
2. J. A. Dyck, G. G. Maul, W. H. Miller, Jr., J. D. Chen, A. Kakizuka and R. M. Evans: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell, 76(2), 333-43(1994) (Pubitemid 24046695)
3. A. M. Ishov, A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss, 3rd and G. G. Maul: PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol, 147(2), 221-34(1999)
4. A. Melnick and J. D. Licht: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, 93(10), 3167-215(1999) (Pubitemid 29220886)
5. Y. Chai, S. L. Koppenhafer, S. J. Shoesmith, M. K. Perez and H. L. Paulson: Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet, 8(4), 673-82(1999) (Pubitemid 29139983)
6. P. J. Skinner, B. T. Koshy, C. J. Cummings, I. A. Klement, K. Helin, A. Servadio, H. Y. Zoghbi and H. T. Orr: Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature, 389(6654), 971-4(1997) (Pubitemid 27485688)
7. S. Yasuda, K. Inoue, M. Hirabayashi, H. Higashiyama, Y. Yamamoto, H. Fuyuhiro, O. Komure, F. Tanaka, G. Sobue, K. Tsuchiya, K. Hamada, H. Sasaki, K. Takeda, H. Ichijo and A. Kakizuka: Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes Cells, 4(12), 743-56(1999) (Pubitemid 30053321)
8. A. Janer, E. Martin, M. P. Muriel, M. Latouche, H. Fujigasaki, M. Ruberg, A. Brice, Y. Trottier and A. Sittler: PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol, 174(1), 65-76(2006) (Pubitemid 43992897)
9. K. L. Borden: Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol, 22(15), 5259-69(2002) (Pubitemid 34755740)
10. G. G. Maul, D. Negorev, P. Bell and A. M. Ishov: Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J Struct Biol, 129(2-3), 278-87(2000) (Pubitemid 30481369)
11. P. Turelli, V. Doucas, E. Craig, B. Mangeat, N. Klages, R. Evans, G. Kalpana and D. Trono: Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell, 7(6), 1245-54(2001) (Pubitemid 32607358)
12. N. Cohen, M. Sharma, A. Kentsis, J. M. Perez, S. Strudwick and K. L. Borden: PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. Embo J, 20(16), 4547-59(2001) (Pubitemid 32772048)
13. B. Culjkovic, I. Topisirovic, L. Skrabanek, M. Ruiz-Gutierrez and K. L. Borden: eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol, 169(2), 245-56(2005) (Pubitemid 40656563)
14. H. K. Lai and K. L. Borden: The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene, 19(13), 1623-34(2000) (Pubitemid 30200964)
15. I. Topisirovic, A. D. Capili and K. L. Borden: Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner. Mol Cell Biol, 22(17), 6183-98(2002) (Pubitemid 34857838)
16. S. O. Boe, M. Haave, A. Jul-Larsen, A. Grudic, R. Bjerkvig and P. E. Lonning: Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci, 119(Pt 16), 3284-95(2006) (Pubitemid 44405214)
17. G. Dellaire, R. W. Ching, K. Ahmed, F. Jalali, K. C. Tse, R. G. Bristow and D. P. Bazett-Jones: Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol, 175(1), 55-66(2006) (Pubitemid 44537198)
18. O. Bischof, S. H. Kim, J. Irving, S. Beresten, N. A. Ellis and J. Campisi: Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol, 153(2), 367-80(2001) (Pubitemid 34280221)
19. R. Carbone, M. Pearson, S. Minucci and P. G. Pelicci: PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene, 21(11), 1633-40(2002) (Pubitemid 34259026)
20. G. Dellaire, R. W. Ching, H. Dehghani, Y. Ren and D. P. Bazett-Jones: The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci, 119(Pt 6), 1026-33(2006)
21. A. Jul-Larsen, T. Visted, B. O. Karlsen, C. H. Rinaldo, R. Bjerkvig, P. E. Lonning and S. O. Boe: PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Exp Cell Res, 298(1), 58-73(2004) (Pubitemid 38887307)
22. J. Burkham, D. M. Coen and S. K. Weller: ND10 protein PML is recruited to herpes simplex virus type 1 prereplicative sites and replication compartments in the presence of viral DNA polymerase. J Virol, 72(12), 10100-7(1998) (Pubitemid 28520880)
23. F. M. Boisvert, M. J. Hendzel and D. P. Bazett-Jones: Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol, 148(2), 283-92(2000) (Pubitemid 30078240)
24. R. W. Ching, G. Dellaire, C. H. Eskiw and D. P. Bazett-Jones: PML bodies: a meeting place for genomic loci? J Cell Sci, 118(Pt 5), 847-54(2005) (Pubitemid 40484877)
25. C. H. Eskiw and D. P. Bazett-Jones: The promyelocytic leukemia nuclear body: sites of activity? Biochem Cell Biol, 80(3), 301-10(2002) (Pubitemid 34748269)
26. B. B. Quimby, V. Yong-Gonzalez, T. Anan, A. V. Strunnikov and M. Dasso: The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene, 25(21), 2999-3005(2006) (Pubitemid 43780464)
27. T. G. Hofmann, A. Moller, H. Sirma, H. Zentgraf, Y. Taya, W. Droge, H. Will and M. L. Schmitz: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol, 4(1), 1-10(2002) (Pubitemid 34071974)
28. M. Pearson, R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli, S. Saito, Y. Higashimoto, E. Appella, S. Minucci, P. P. Pandolfi and P. G. Pelicci: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 406(6792), 207-10(2000) (Pubitemid 30469006)
29. K. Mattsson, K. Pokrovskaja, C. Kiss, G. Klein and L. Szekely: Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasomedependent protein degradation. Proc Natl Acad Sci U S A, 98(3), 1012-7(2001) (Pubitemid 32121178)
30. R. Bernardi, P. P. Scaglioni, S. Bergmann, H. F. Horn, K. H. Vousden and P. P. Pandolfi: PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol, 6(7), 665-72(2004) (Pubitemid 38960925)
31. L. Janderova-Rossmeislova, Z. Novakova, J. Vlasakova, V. Philimonenko, P. Hozak and Z. Hodny: PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells. J Struct Biol, 159(1), 56-70(2007) (Pubitemid 46880553)
32. M. Muratani, D. Gerlich, S. M. Janicki, M. Gebhard, R. Eils and D. L. Spector: Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat Cell Biol, 4(2), 106-10(2002) (Pubitemid 34141475)
33. C. H. Eskiw, G. Dellaire, J. S. Mymryk and D. P. Bazett-Jones: Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J Cell Sci, 116(Pt 21), 4455-66(2003) (Pubitemid 37369600)
34. S. Strudwick and K. L. Borden: Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia, 16(10), 1906-17(2002) (Pubitemid 35203433)
35. T. G. Hofmann and H. Will: Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ, 10(12), 1290-9(2003) (Pubitemid 37536734)
36. M. N. Boddy, E. Duprez, K. L. Borden and P. S. Freemont: Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrixassociated PML bodies. J Cell Sci, 110(Pt 18), 2197-205(1997) (Pubitemid 27448364)
37. E. Duprez, A. J. Saurin, J. M. Desterro, V. Lallemand-Breitenbach, K. Howe, M. N. Boddy, E. Solomon, H. de The, R. T. Hay and P. S. Freemont: SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci, 112(Pt 3), 381-93(1999) (Pubitemid 29080660)
38. I. Topisirovic, B. Culjkovic, N. Cohen, J. M. Perez, L. Skrabanek and K. L. Borden: The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. Embo J, 22(3), 689-703(2003) (Pubitemid 36193613)
39. Z. G. Wang, L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld and P. P. Pandolfi: Role of PML in cell growth and the retinoic acid pathway. Science, 279(5356), 1547-51(1998) (Pubitemid 28217080)
40. V. Lang, N. I. Zanchin, H. Lunsdorf, M. Tuite and J. E. McCarthy: Initiation factor eIF-4E of Saccharomyces cerevisiae. Distribution within the cell, binding to mRNA, and consequences of its overproduction. J Biol Chem, 269(8), 6117-23(1994)
41. F. Lejbkowicz, C. Goyer, A. Darveau, S. Neron, R. Lemieux and N. Sonenberg: A fraction of the mRNA 5' cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc Natl Acad Sci U S A, 89(20), 9612-6(1992)
42. R. Bernardi, I. Guernah, D. Jin, S. Grisendi, A. Alimonti, J. Teruya-Feldstein, C. Cordon-Cardo, M. C. Simon, S. Rafii and P. P. Pandolfi: PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature, 442(7104), 779-85(2006) (Pubitemid 44258904)
43. F. Quignon, F. De Bels, M. Koken, J. Feunteun, J. C. Ameisen and H. de The: PML induces a novel caspaseindependent death process. Nat Genet, 20(3), 259-65(1998) (Pubitemid 28507670)
44. Y. Joe, J. H. Jeong, S. Yang, H. Kang, N. Motoyama, P. P. Pandolfi, J. H. Chung and M. K. Kim: ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem, 281(39), 28764-71(2006) (Pubitemid 44507019)
45. B. Culjkovic, I. Topisirovic, L. Skrabanek, M. Ruiz-Gutierrez and K. L. Borden: eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol, 175(3), 415-26(2006) (Pubitemid 44708066)
46. G. Ferbeyre, E. de Stanchina, E. Querido, N. Baptiste, C. Prives and S. W. Lowe: PML is induced by oncogenic ras and promotes premature senescence. Genes Dev, 14(16), 2015-27(2000) (Pubitemid 30637352)
47. M. A. Grande, I. van der Kraan, B. van Steensel, W. Schul, H. de The, H. T. van der Voort, L. de Jong and R. van Driel: PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components. J Cell Biochem, 63(3), 280-91(1996) (Pubitemid 26371554)
48. J. M. Woulfe, W. Prichett-Pejic, P. Rippstein and D. G. Munoz: Promyelocytic leukaemia-immunoreactive neuronal intranuclear rodlets in the human brain. Neuropathol Appl Neurobiol, 33(1), 56-66(2007) (Pubitemid 46090310)
49. G. C. Scheper, J. L. Parra, M. Wilson, B. Van Kollenburg, A. C. Vertegaal, Z. G. Han and C. G. Proud: The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol Cell Biol, 23(16), 5692-705(2003) (Pubitemid 36951333)
50. K. L. Borden, E. J. Campbelldwyer, G. W. Carlile, M. Djavani and M. S. Salvato: Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. J Virol, 72(5), 3819-26(1998) (Pubitemid 28188681)
51. C. Desbois, R. Rousset, F. Bantignies and P. Jalinot: Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science, 273(5277), 951-3(1996) (Pubitemid 26275170)
52. G. W. Carlile, W. G. Tatton and K. L. Borden: Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Biochem J, 335(Pt 3), 691-6(1998) (Pubitemid 28515425)
53. E. Nagy and W. F. Rigby: Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD (+)-binding region (Rossmann fold). J Biol Chem, 270(6), 2755-63(1995)
54. R. Singh and M. R. Green: Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science, 259(5093), 365-8(1993) (Pubitemid 23055678)
55. M. N. Harris, B. Ozpolat, F. Abdi, S. Gu, A. Legler, K. G. Mawuenyega, M. Tirado-Gomez, G. Lopez-Berestein and X. Chen: Comparative proteomic analysis of all-transretinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood, 104(5), 1314-23(2004) (Pubitemid 39166505)
56. W. Condemine, Y. Takahashi, M. Le Bras and H. de The: A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell Sci, 120(Pt 18), 3219-27(2007) (Pubitemid 350018413)
57. H. Seker, C. Rubbi, S. P. Linke, E. D. Bowman, S. Garfield, L. Hansen, K. L. Borden, J. Milner and C. C. Harris: UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene, 22(11), 1620-8(2003) (Pubitemid 36408177)
58. A. Kentsis, E. C. Dwyer, J. M. Perez, M. Sharma, A. Chen, Z. Q. Pan and K. L. Borden: The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol, 312(4), 609-23(2001) (Pubitemid 33116728)
59. M. N. Boddy, K. Howe, L. D. Etkin, E. Solomon and P. S. Freemont: PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene, 13(5), 971-82(1996) (Pubitemid 26329084)
60. V. Lallemand-Breitenbach, J. Zhu, F. Puvion, M. Koken, N. Honore, A. Doubeikovsky, E. Duprez, P. P. Pandolfi, E. Puvion, P. Freemont and H. de The: Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med, 193(12), 1361-71(2001) (Pubitemid 32565965)
61. B. Culjkovic, I. Topisirovic and K. L. Borden: Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle, 6(1), 65-9(2007) (Pubitemid 46173883)
62. S. Strudwick and K. L. Borden: The emerging roles of translation factor eIF4E in the nucleus. Differentiation, 70(1), 10-22(2002) (Pubitemid 38232695)
63. J. D. Keene: RNA regulons: coordination of posttranscriptional events. Nat Rev Genet, 8(7), 533-43(2007) (Pubitemid 46955210)
64. J. D. Keene and P. J. Lager: Post-transcriptional operons and regulons co-ordinating gene expression. Chromosome Res, 13(3), 327-37(2005)
65. O. Bischof, O. Kirsh, M. Pearson, K. Itahana, P. G. Pelicci and A. Dejean: Deconstructing PML-induced premature senescence. Embo J, 21(13), 3358-69(2002) (Pubitemid 34760568)
66. S. Yang, C. Kuo, J. E. Bisi and M. K. Kim: PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol, 4(11), 865-70(2002) (Pubitemid 35331361)
67. E. de Stanchina, E. Querido, M. Narita, R. V. Davuluri, P. P. Pandolfi, G. Ferbeyre and S. W. Lowe: PML is a direct p53 target that modulates p53 effector functions. Mol Cell, 13(4), 523-35(2004) (Pubitemid 38299380)
68. I. Louria-Hayon, T. Grossman, R. V. Sionov, O. Alsheich, P. P. Pandolfi and Y. Haupt: The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem, 278(35), 33134-41(2003) (Pubitemid 37055760)
69. S. Kurki, L. Latonen and M. Laiho: Cellular stress and DNA damage invoke temporally distinct Mdm 2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci, 116(Pt 19), 3917-25(2003) (Pubitemid 37279307)
70. G. D'Orazi, B. Cecchinelli, T. Bruno, I. Manni, Y. Higashimoto, S. Saito, M. Gostissa, S. Coen, A. Marchetti, G. Del Sal, G. Piaggio, M. Fanciulli, E. Appella and S. Soddu: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol, 4(1), 11-9(2002)
71. A. Phillips and J. P. Blaydes: MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene (2007)
72. M. Phelps, A. Phillips, M. Darley and J. P. Blaydes: MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem, 280(17), 16651-8(2005) (Pubitemid 41389122)
73. N. Zhu, L. Gu, H. W. Findley and M. Zhou: Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem Biophys Res Commun, 335(4), 1272-9(2005) (Pubitemid 41215554)
74. X. Wei, Z. K. Yu, A. Ramalingam, S. R. Grossman, J. H. Yu, D. B. Bloch and C. G. Maki: Physical and functional interactions between PML and MDM2. J Biol Chem, 278(31), 29288-97(2003) (Pubitemid 36935845)
75. L. E. Horton, M. Bushell, D. Barth-Baus, V. J. Tilleray, M. J. Clemens and J. O. Hensold: p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene, 21(34), 5325-34(2002) (Pubitemid 34948143)
76. L. C. Trotman, A. Alimonti, P. P. Scaglioni, J. A. Koutcher, C. Cordon-Cardo and P. P. Pandolfi: Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441(7092), 523-7(2006) (Pubitemid 44050155)
77. Y. C. Chen, Y. N. Su, P. C. Chou, W. C. Chiang, M. C. Chang, L. S. Wang, S. C. Teng and K. J. Wu: Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J Biol Chem, 280(37), 32505-11(2005)
78. D. Sagan, S. Mortl, I. Muller, F. Eckardt-Schupp and H. Eichholtz-Wirth: Enhanced CD95-mediated apoptosis contributes to radiation hypersensitivity of NBS lymphoblasts. Apoptosis, 12(4), 753-67(2007) (Pubitemid 46411471)
79. K. L. Borden, E. J. CampbellDwyer and M. S. Salvato: The promyelocytic leukemia protein PML has a proapoptotic activity mediated through its RING domain. FEBS Lett, 418(1-2), 30-4(1997) (Pubitemid 27514409)
80. Z. G. Wang, D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi and P. P. Pandolfi: PML is essential for multiple apoptotic pathways. Nat Genet, 20(3), 266-72(1998) (Pubitemid 28507671)
81. A. De Benedetti and J. R. Graff: eIF-4E expression and its role in malignancies and metastases. Oncogene, 23(18), 3189-99(2004) (Pubitemid 38638830)
82. J. R. Graff, B. W. Konicek, T. M. Vincent, R. L. Lynch, D. Monteith, S. N. Weir, P. Schwier, A. Capen, R. L. Goode, M. S. Dowless, Y. Chen, H. Zhang, S. Sissons, K. Cox, A. M. McNulty, S. H. Parsons, T. Wang, L. Sams, S. Geeganage, L. E. Douglass, B. L. Neubauer, N. M. Dean, K. Blanchard, J. Shou, L. F. Stancato, J. H. Carter and E. G. Marcusson: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest, 117(9), 2638-48(2007) (Pubitemid 47494364)
83. N. Sonenberg: Translation factors as effectors of cell growth and tumorigenesis. Curr Opin Cell Biol, 5(6), 955-60(1993) (Pubitemid 23340500)
84. M. J. Clemens and U. A. Bommer: Translational control: the cancer connection. Int J Biochem Cell Biol, 31(1), 1-23(1999) (Pubitemid 29094785)
85. Z. M. Mu, X. F. Le, S. Vallian, A. B. Glassman and K. S. Chang: Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis, 18(11), 2063-9(1997) (Pubitemid 28134730)
86. S. H. Son, E. Yu, E. K. Choi, H. Lee and J. Choi: Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells. Cancer Gene Ther, 12(1), 1-11(2005) (Pubitemid 39665237)
87. B. Terris, V. Baldin, S. Dubois, C. Degott, J. F. Flejou, D. Henin and A. Dejean: PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res, 55(7), 1590-7(1995)
88. C. Gurrieri, P. Capodieci, R. Bernardi, P. P. Scaglioni, K. Nafa, L. J. Rush, D. A. Verbel, C. Cordon-Cardo and P. P. Pandolfi: Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst, 96(4), 269-79(2004) (Pubitemid 38256272)
89. W. Condemine, Y. Takahashi, J. Zhu, F. Puvion-Dutilleul, S. Guegan, A. Janin and H. de The: Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res, 66(12), 6192-8(2006)
90. J. Y. Chan, W. Chin, C. T. Liew, K. S. Chang and P. J. Johnson: Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer, 34(7), 1015-22(1998) (Pubitemid 28308341)
91. M. J. Karkkainen and T. V. Petrova: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene, 19(49), 5598-605(2000)
92. S. Shinkaruk, M. Bayle, G. Lain and G. Deleris: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents, 3(2), 95-117(2003) (Pubitemid 36221732)
93. A. Guo, P. Salomoni, J. Luo, A. Shih, S. Zhong, W. Gu and P. P. Pandolfi: The function of PML in p53-dependent apoptosis. Nat Cell Biol, 2(10), 730-6(2000)
94. I. Topisirovic, A. Kentsis, J. M. Perez, M. L. Guzman, C. T. Jordan and K. L. Borden: Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol, 25(3), 1100-12(2005) (Pubitemid 40165816)
95. I. Topisirovic and K. L. Borden: Homeodomain proteins and eukaryotic translation initiation factor 4E (eIF4E): an unexpected relationship. Histol Histopathol, 20(4), 1275-84(2005) (Pubitemid 41489170)
96. A. Kentsis, R. E. Gordon and K. L. Borden: Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci U S A, 99(24), 15404-9(2002) (Pubitemid 35403947)
97. A. Kentsis, R. E. Gordon and K. L. Borden: Selfassembly properties of a model RING domain. Proc Natl Acad Sci U S A, 99(2), 667-72(2002) (Pubitemid 34106569)
98. M. V. Poyurovsky, C. Priest, A. Kentsis, K. L. Borden, Z. Q. Pan, N. Pavletich and C. Prives: The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. Embo J, 26(1), 90-101(2007) (Pubitemid 46094702)
99. D. Negorev and G. G. Maul: Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene, 20(49), 7234-42(2001) (Pubitemid 33105012)
100. K. Naka, K. Ikeda and N. Motoyama: Recruitment of NBS1 into PML oncogenic domains via interaction with SP100 protein. Biochem Biophys Res Commun, 299(5), 863-71(2002) (Pubitemid 36034566)
101. M. Fagioli, M. Alcalay, P. P. Pandolfi, L. Venturini, A. Mencarelli, A. Simeone, D. Acampora, F. Grignani and P. G. Pelicci: Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene, 7(6), 1083-91(1992)
102. L. Flenghi, M. Fagioli, L. Tomassoni, S. Pileri, M. Gambacorta, R. Pacini, F. Grignani, T. Casini, P. F. Ferrucci, M. F. Martelli and et al.: Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood, 85(7), 1871-80(1995)
103. K. Jensen, C. Shiels and P. S. Freemont: PML protein isoforms and the RBCC/TRIM motif. Oncogene, 20(49), 7223-33(2001) (Pubitemid 33105011)
104. G. Dellaire, C. H. Eskiw, H. Dehghani, R. W. Ching and D. P. Bazett-Jones: Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci, 119(Pt 6), 1034-42(2006)
105. K. L. Borden, E. J. Campbell Dwyer and M. S. Salvato: An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J Virol, 72(1), 758-66(1998) (Pubitemid 28048896)
106. C. Gurrieri, K. Nafa, T. Merghoub, R. Bernardi, P. Capodieci, A. Biondi, S. Nimer, D. Douer, C. Cordon-Cardo, R. Gallagher and P. P. Pandolfi: Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 103(6), 2358-62(2004) (Pubitemid 38326258)
107. P. Zheng, Y. Guo, Q. Niu, D. E. Levy, J. A. Dyck, S. Lu, L. A. Sheiman and Y. Liu: Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature, 396(6709), 373-6(1998) (Pubitemid 28557398)
108. C. Bellodi, K. Kindle, F. Bernassola, D. Dinsdale, A. Cossarizza, G. Melino, D. Heery and P. Salomoni: Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem, 281(20), 14465-73(2006) (Pubitemid 43848377)
109. C. Bellodi, K. Kindle, F. Bernassola, A. Cossarizza, D. Dinsdale, G. Melino, D. Heery and P. Salomoni: A cytoplasmic PML mutant inhibits p53 function. Cell Cycle, 5(22), 2688-92(2006) (Pubitemid 44785813)
110. F. A. Mallette, S. Goumard, M. F. Gaumont-Leclerc, O. Moiseeva and G. Ferbeyre: Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene, 23(1), 91-9(2004) (Pubitemid 38142243)
111. X. F. Le, P. Yang and K. S. Chang: Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem, 271(1), 130-5(1996) (Pubitemid 26026568)
112. M. Fagioli, M. Alcalay, L. Tomassoni, P. F. Ferrucci, A. Mencarelli, D. Riganelli, F. Grignani, T. Pozzan, I. Nicoletti and P. G. Pelicci: Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene, 16(22), 2905-13(1998) (Pubitemid 28383275)
113. H. K. Lin, S. Bergmann and P. P. Pandolfi: Cytoplasmic PML function in TGF-beta signalling. Nature, 431(7005), 205-11(2004) (Pubitemid 39243475)
114. S. R. Seo, N. Ferrand, N. Faresse, C. Prunier, L. Abecassis, M. Pessah, M. F. Bourgeade and A. Atfi: Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol Cell, 23(4), 547-59(2006) (Pubitemid 44226449)
115. M. M. Shull, I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin and et al.: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature, 359(6397), 693-9(1992)
116. A. B. Kulkarni, C. G. Huh, D. Becker, A. Geiser, M. Lyght, K. C. Flanders, A. B. Roberts, M. B. Sporn, J. M. Ward and S. Karlsson: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A, 90(2), 770-4(1993) (Pubitemid 23028947)
117. M. Nomura and E. Li: Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature, 393(6687), 786-90(1998) (Pubitemid 28299489)
118. X. Yang, J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts and C. Deng: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. Embo J, 18(5), 1280-91(1999) (Pubitemid 29110312)